Stocks Health care KPRX
NASDAQ · Health careKiora Pharmaceuticals Inc (KPRX)
It posted a net loss of $11M. In fiscal 2025 capital spending exceeded operating cash flow by $10.1M. At June 30, 2026 it held $7.1M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 7, 2026.
Watch KPRX in 60 secondsWhat Kiora Pharmaceuticals Inc does
Kiora Pharmaceuticals Inc is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker KPRX.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $0 | -$10.8M | -$2.64 | -$10.1M |
| 2024 | $16M | $3.6M | $0.87 | $8.6M |
| 2023 | $0 | -$12.5M | -$24.25 | -$9.6M |
| 2022 | n/a | -$13.6M | -$167.23 | -$10.4M |
| 2021 | $0 | -$13.8M | -$514.93 | -$10.7M |
| 2020 | $12.1K | -$6.9M | -$536.53 | -$7.3M |
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Kiora Pharmaceuticals Inc has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 17, 2026Passive stake (5% or more) SCHEDULE 13G
- September 8, 2026
- August 19, 2026
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 10, 2026Passive stake (5% or more) SCHEDULE 13G
- August 7, 2026
- August 7, 2026
- June 18, 2026
- June 11, 2026
Insider trades
What the people running Kiora Pharmaceuticals Inc did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider bought or sold shares on the open market in the last 90 days. The 2 reported changes were pay in shares, option exercises, shares withheld for tax or gifts.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| July 1, 2026 | Strem Brian M.President and CEO, Director | Shares withheld for tax | 1,869 | $5K |
| July 1, 2026 | Tosca MelissaCFO | Shares withheld for tax | 911 | $2.4K |
Who owns KPRX
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Alyeska Investment Group, L.P.13G, passive with 2 related filers | 9.99% | May 15, 2026 |
| Nantahala Capital Management, LLC13G, passive with 2 related filers | 9.99% | August 14, 2026 |
| Perceptive Advisors LLC13G, passive with 2 related filers | 9.99% | August 10, 2026 |
| Stonepine Capital Management, LLC13G, passive with 3 related filers | 9.99% | November 13, 2024 |
| ADAR1 Capital Management GP, LLC13G, passive with 2 related filers | 9.9% | August 14, 2026 |
| Rosalind Advisors, Inc.13G, passive with 3 related filers | 9.9% | February 11, 2026 |
| The Goldman Sachs Group, Inc. ------------------------------------------------------------------------------13G, passive with 1 related filers | 6.1% | November 12, 2024 |
| Baselake Partners, LP13G, passive with 2 related filers | 5.8% | September 17, 2026 |
Largest institutional holders
Insiders
2 insiders reported holding 84,887 shares in total, about $226.6K at the last price.
| Holder | Shares |
|---|---|
| Strem Brian M.President and CEO, Director | 58,823 |
| Tosca MelissaCFO | 26,064 |
Questions about KPRX
What does Kiora Pharmaceuticals Inc do?
Kiora Pharmaceuticals Inc is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker KPRX.
Is Kiora Pharmaceuticals Inc profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $11M.
When did Kiora Pharmaceuticals Inc last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 7, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the passive stake (5% or more) from September 17, 2026.
Similar companies
Compare KPRX with
Follow KPRX
Get an email when Kiora Pharmaceuticals Inc files with the SEC: results, executive changes, material agreements and annual reports.
Follow KPRX: get an email when it filesWhere the numbers come from
Financial figures are the values Kiora Pharmaceuticals Inc tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.